Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $141.10 | Total: $705.50 |
| 1 | 10 | $119.52 | Total: $1,195.20 |
| 1 | 25 | $101.26 | Total: $2,531.50 |
| 1 | 50 | $86.32 | Total: $4,316.00 |
| 1 | 100 | $74.70 | Total: $7,470.00 |
Overview
Enrasentan (sb-217242) is a mixed antagonist of ET(A) and ET(B) receptors that reduces blood pressure, prevents cardiac hypertrophy, and protects myocardial function.
Chemical Properties
| Molecular Formula | C29H30O8 |
| Molecular Weight | 506.54 |
| CAS Numbers | 167256-08-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(O)(=O)[C@H]1[C@@H](C=2C([C@@H]1C=3C=C4C(=CC3)OCO4)=CC=C(OCCC)C2)C5=C(OCCO)C=C(OC)C=C5 |
Storage and Handling
0C Short Term, -20C Long Term
References
Cosenzi A,et al. Antihypertensive treatment with enrasentan [SB217242] in an animal model of hypertension and hyperinsulinemia. J Cardiovasc Pharmacol. 2002 Apr;39[4] 488-95.